RAFAEL HOLDINGS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
RAFAEL HOLDINGS, INC. (RFL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$32.34 million for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$32.34M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$67.65M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$122.83M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$22.84M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-07-31 | -$32.34M 10-K · filed 2025-10-29 |
| 2024-07-31 | -$67.65M 10-K · filed 2025-10-29 |
| 2022-07-31 | -$122.83M 10-K · filed 2022-10-31 |
| 2021-07-31 | -$22.84M 10-K · filed 2022-10-31 |
| 2020-07-31 | -$10.24M 10-K · filed 2020-10-29 |
| 2019-07-31 | -$3.41M 10-K · filed 2020-10-29 |
| 2018-07-31 | -$2.58M 10-K · filed 2019-10-04 |
| 2017-07-31 | $97.00K 10-K · filed 2018-10-15 |
| 2016-07-31 | $1.10M 10-K · filed 2018-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |